ALK^+弥漫大B细胞淋巴瘤患者临床决策探讨

Clinical decision on a patient with ALK^+ diffuse large B cell lymphoma

ALK^+弥漫大B细胞淋巴瘤(anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma,ALK^+DLBCL)是淋巴瘤中一种罕见的和具有明显差异性的病理类型,2008年WHO将其归类为DLBCL一个独特的亚型,该病侵袭性高,容易复发,目前尚无规范有效的治疗方案。采取多学科协作体系(multidisciplinary treatment,MDT)有利于制定规范化、个体化的治疗方案,探索针对ALK^+DLBCL患者更有效的治疗方法,从而让更多的患者获益。本研究分享1例2012年1月天津医科大学肿瘤医院收治的ALK^+DLBCL高剂量化疗联合自体造血干细胞移植(autologous hematopoietic stem cell transplantation,AHSCT)后复发,采用ALK激酶抑制剂克唑替尼(Crizotinib)治疗成功的案例。

Anaplastic lymphoma kinase（ALK）-positive diffuse large B-cell lymphoma（DLBCL） is a rare and distinct variant of DLBCL. It is classified as a unique subtype of DLBCL in the 2008 WHO classification of lymphomas. No standard and effective therapeutic regimen is available for ALK~＋DLBCL because it shows a more aggressive clinical course and frequent relapse. Therefore, a standardized and individualized treatment is needed to benefit more patients diagnosed with ALK~＋DLBCL through a multiple disciplinary team. This article presents a case of an ALK~＋DLBCL patient who relapsed after transplantation and was successfully treated with the ALK kinase inhibitor Crizotinib.